Study guide
4.2 Written Directives and DOT Shipping
Certified Nuclear Medicine Technologist CNMT
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Overview
1.1 Current CNMT Exam Facts 1.2 How to Use This Guide
2 Radiation Physics Fundamentals
2.1 Radioactive Materials, Isotopes, and Decay Modes 2.2 Decay Calculations and Counting Statistics 2.3 Interactions of Radiation with Matter 2.4 Radiation Detector Types and Principles
3 Biological Effects & ALARA
3.1 Biological Effects of Radiation Exposure 3.2 ALARA and Protection Calculations 3.3 Dose Limits, Surveys, and Personal Monitoring
4 NRC & Regulatory Compliance
4.1 NRC Areas, Spills, Waste, and Records 4.2 Written Directives and DOT Shipping 4.3 EPA, OSHA, HIPAA, FDA, and USP Standards 4.4 Radioactive Waste Disposal and Regulatory Records
5 Generators & Kit Preparation
5.1 Radionuclide Generators and Quality Control 5.2 Radiopharmaceutical Kit Preparation 5.3 Radiopharmaceutical Quality Control
6 Tc-99m Diagnostic Agents
6.1 Tc-99m Cardiac Imaging Agents 6.2 Tc-99m Bone, Renal, and GU Agents 6.3 Tc-99m GI and Hepatobiliary Agents 6.4 Tc-99m CNS, Infection, and Labeled Cells
7 Non-Tc Diagnostic & PET Agents
7.1 Iodine and Indium Diagnostic Agents 7.2 Gallium, Thallium, Xenon, and Miscellaneous Agents 7.3 PET Radiopharmaceuticals 7.4 Neurologic, Breast, and Neuroendocrine PET Agents
8 Therapeutics, Adjuncts & Administration
8.1 Therapeutic Radiopharmaceuticals 8.2 Interventional and Adjunct Pharmaceuticals 8.3 Blood Labeling and Administration Techniques 8.4 Blockade, Comfort, and Gastrointestinal Adjunct Agents
9 Non-Imaging Instrumentation
9.1 Well Counters, Probes, and Survey Meters 9.2 Dose Calibrator Quality Control 9.3 Auxiliary and Patient Care Equipment
10 Imaging Systems & Quality Control
10.1 Gamma Camera Quality Control 10.2 SPECT and SPECT/CT Systems 10.3 PET and PET/CT Systems and QC 10.4 CT Systems, PACS, and Information Systems 10.5 CT Radiation Dose, Safety Alerts, and Protocol Optimization
11 Pulmonary, Bone, Oncology & Infection Imaging
11.1 Pulmonary Imaging Procedures 11.2 Bone and Musculoskeletal Imaging 11.3 Oncology Imaging Procedures 11.4 Infection Imaging Procedures
12 Renal, Endocrine & Hematopoietic Imaging
12.1 Renal and Genitourinary Imaging 12.2 Endocrine Imaging (Thyroid, Parathyroid, Adrenal) 12.3 Hematopoietic and Bone Marrow Imaging 12.4 Thyroid Uptake Measurement and Radioiodine Survey Technique
13 Cardiovascular Procedures
13.1 Myocardial Perfusion Imaging 13.2 Cardiac Function, Viability, and Special Studies 13.3 Exercise and Pharmacologic Stress Testing
14 GI, CNS, Therapy & Hybrid CT Procedures
14.1 Gastrointestinal Procedures 14.2 Central Nervous System Procedures 14.3 Radionuclide Therapy Procedures 14.4 CT and Hybrid Imaging in Nuclear Medicine 14.5 CSF Studies: Cisternography, Leak Localization, and Shunt Patency
15 Patient Care & Clinical Workflow
15.1 Patient Care, Education, and Consent 15.2 Scheduling and Radiopharmaceutical Procurement 15.3 Acquisition, Positioning, and Image Quality 15.4 Image Processing and Quantitative Analysis 15.5 Non-Imaging Studies: Specimens, Counting, and Error Analysis
4.2 Written Directives and DOT Shipping
Key Takeaways Explain This Topic AI
A written directive is required before I-131 sodium iodide > 30 µCi and before therapeutic dosages of unsealed byproduct material (and other Part 35 therapy uses)
Unsealed-therapy written directives must identify the patient, radiopharmaceutical, dosage, and route, and be signed/dated by the authorized user before administration
Most radiopharmaceutical shipments use Type A packaging with White-I, Yellow-II, or Yellow-III labels based on surface dose rate and Transportation Index (dose rate at 1 m)
Labeled packages must be surveyed (surface and 1 m as applicable) and wipe-tested within 3 hours of receipt during working hours; elevated readings trigger RSO, carrier, and NRC notification pathways
Unit-dose and shipping labels must state identity, activity, assay date/time, and related concentration/expiration data so assays and administrations match the prescription
Last updated: August 2026
Two high-yield streams often appear together on CNMT items: written directives (WD) for medical use under 10 CFR Part 35 , and DOT rules for shipping and receiving packages. One protects the patient from wrong therapy; the other protects workers, carriers, and the public in transit.
Written Directives: When Required
A written directive is an authorized user’s written order for a specific patient before certain administrations. You must have a WD before :
Situation WD required?
I-131 NaI > 30 µCi (1.11 MBq) Yes
Any therapeutic dosage of unsealed byproduct material ( I-131 therapy, Lu-177 , Ra-223 , Y-90 under applicable medical-use rules, Sm-153 , etc.) Yes
- Routine diagnostic Tc-99m, F-18, etc. No WD (still need order + identity checks)
- Other Part 35 sealed-source therapies Yes (format differs)
Exam trap: I-131 sodium iodide above 30 µCi always pulls WD rules. Therapy nuclides ( Lu-177 , Y-90 , high-activity I-131 ) are classic WD scenarios.
Required Elements
For unsealed byproduct material , the WD must include at least:
- Patient’s name (clear identity)
- Radioactive drug
- Dosage (activity)
- Route of administration
- Authorized user signature and date — before administration
For I-131 NaI > 30 µCi , rules emphasize patient name, dosage, and AU signature/date; still verify identity and order in practice.
Before you dose
Verify two patient identifiers against the WD and order.
Confirm radiopharmaceutical, activity, and route match the WD.
Assay in the dose calibrator; document measured activity and time.
If activity is outside the prescribed range or WD, stop and contact the AU.
After administration, record what was given. Technologists do not freestyle therapy activities.
Written directives sit inside quality management : policies to catch wrong patient, wrong drug, wrong route, and dosage errors before they become medical events (Section 4.1).
DOT Packaging Basics
Radiopharmaceuticals move under DOT Hazardous Materials rules. Most unit doses and many generator-related shipments arrive in Type A packages—tested for normal transport conditions within Type A_1/A_2 activity limits.
- Package class Typical NM use
- Excepted Very low activity; limited markings
- Type A Routine radiopharmacy shipments, generators within limits
- Type B Higher activity; more robust packaging (less common on the imaging floor)
Outer packaging preserves containment and shielding. Inner pigs (lead/tungsten) cut external dose; the outer container provides impact protection and a labeling surface.
Labels and Transportation Index
- Label Surface dose rate (approx. max) At 1 m / TI
- White-I ≤ 0.5 mrem/h (0.005 mSv/h) TI = 0 (≤ 0.05 mrem/h at 1 m)
- Yellow-II ≤ 50 mrem/h (0.5 mSv/h) TI ≤ 1.0
- Yellow-III ≤ 200 mrem/h (2 mSv/h) TI ≤ 10 (vehicle/placard rules may apply)
The Transportation Index (TI) equals the maximum dose rate at 1 meter in mrem/h , rounded up to the nearest tenth (0.13 mrem/h → TI 0.2 ). TI drives segregation and storage distance. Labels also show radionuclide and activity . Do not cover required labels in transit; empty returns must have radiation labels removed or obliterated when no longer applicable.
Package Monitoring on Receipt
Under 10 CFR 20.1906 and license procedures, for White-I / Yellow-II / Yellow-III packages (and certain other cases):
Visually inspect for damage or wetness.
Within 3 hours of receipt during working hours (or within 3 hours of the next working day’s start if after hours), measure external radiation (surface and, as required, 1 m ) and removable contamination with wipe tests .
Compare with regulatory/package limits and internal triggers.
If limits are exceeded or damage is suspected, notify the RSO , and when required the carrier and NRC , and isolate the package.
Do not open a crushed, leaking, or unexpectedly “hot” package at the front desk. Use PPE, shield as needed, and follow RSO direction.
Returns and product labels
Empty pigs returned to a pharmacy must not display active radiation labels if empty (or must be labeled correctly if residual activity remains). Survey/wipe returnables so you do not ship contamination to the vendor.
- Container Purpose
- Lead/tungsten vial pig External dose reduction for vials
- Syringe shield Hand/body protection during draw/inject
- L-block Body shielding while compounding/drawing
- Type A outer package Transport integrity + label surface
Unit-dose / shipping label content typically includes radiopharmaceutical name , activity , assay date/time , concentration and/or volume when relevant, expiration / beyond-use time, patient or unit-dose identifiers, and lot/batch data as required. Reconcile label, assay, order/WD, and patient—decay may make a delayed labeled activity wrong for administration time.
Exam Hooks
Therapy Lu-177 or I-131 without AU-signed WD → stop .
I-131 NaI > 30 µCi → WD required.
Surface 0.4 mrem/h, negligible at 1 m → White-I .
Surface 20 mrem/h, 0.7 mrem/h at 1 m → Yellow-II , TI 0.7 .
Yellow-II arrives 10:00 on a workday → survey/wipe by 13:00 .
Crushed package, high wipes → RSO + isolate + notifications .